


## **AMENDMENTS TO THE CLAIMS**

Please cancel Claims 23-35 and insert therefor Claims 36-49 as follow. This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims:**

Claims 1-35 (Canceled)

36. (New) A compound of the formula (I):



wherein:

R<sup>1</sup> is quinolinyl or isoquinolinyl,

wherein the ring containing the nitrogen atom is unsubstituted or substituted with one or more substituents that are independently selected from R<sup>4</sup>, wherein R<sup>4</sup> represents a hydrogen atom, lower alkyl group, lower alkyloxy group, halogen atom, mono- or di- lower alkylamino atom, hydroxy group, lower alkyloxycarbonyl group, carbamoyl group or mono- or di- lower alkylcarbamoylamino group;

and wherein the ring that does not contain the nitrogen atom is unsubstituted or substituted with one, two or three substituents that are independently selected from substituted group  $\alpha$ ;

R<sup>2</sup> represents a group selected from the group consisting of: hydrogen atom, lower alkyl group, cyano group, lower alkyloxy group, lower alkyloxycarbonyl group and trialkylsilyl group;

R<sup>3</sup> is a phenyl group that may have 1 to 3 substituted groups selected from the group comprising halogen atom, lower alkyl group, cyano group, nitro group, lower alkyloxy group, hydroxy group and amino group, wherein said lower alkyl group may be substituted by a halogen atom;

wherein substituted group  $\alpha$  is selected from: lower alkyl group (the lower alkyl group may be substituted by a hydroxyl group, halogen atom, aryl group di-lower alkylamino group (two di-lower alkyl groups may bound each other and form a 5- to 7- membered aliphatic hetero ring together with nitrogen atom, or 1 of the carbon atom constituting the aliphatic hetero ring may be substituted by an oxygen atom), lower alkoxy group, oxo group, lower alkyloxycarbonyl group, alkanoyloxy group or lower alkylsulfonylamino group; or when the lower alkyl group is a branched-lower alkyl group, the branched alkyls group may bound each other to form a cycloalkyl group or a cycloalkylene group with 3 to 6 carbon atoms, when the lower alkyl group is a branched-lower alkyl group, the branched alkyl groups may be bound each other to form a cycloalkyl group (the cycloalkyl group may be substituted by a lower alkyl group, hydroxy group, aralkyl group, or lower alkoxy group), when the same carbon atom constituting A ring has 2 lower alkyl groups, the lower alkyl group may form together a cycloalkyl group), cycloalkyl group (any 1 of carbon atoms constituting the cycloalkyl group may be substituted by an oxygen atom), lower alkyloxy group, halogen atom, mono- or di-lower alkylamino group, alkanoyl group, alkylsulfonyl group, lower alkyloxycarbonyl group, carbamoyl group, mono- or di-lower alkylcarbamoyl group, mono- or di-lower alkylcarbamoylamino group, amino group and hydroxyl group;

or a pharmaceutically acceptable salt thereof.

37. (New) The compound of Claim 36 wherein  $R^1$  is selected from the group consisting of: quinoline-6-yl, quinoline-7-yl, isoquinoline-7-yl, isoquinoline-6-yl, 2-methylquinoline-6-yl, isoquinoline-3-yl, 2-methoxyquinoline-6-yl, 3-methoxyquinoline-6-yl, 2-dimethylaminoquinoline-6-yl, 2-chloro-3-ethyl-quinoline-6-yl, 2-morpholine-4-yl-quinoline-6-yl, 2-(4-methylpiperazine-1-yl)-quinoline-6-yl, 2-pyrrolidine-1-yl-quinoline-6-yl, 2-methanesulfonyl-quinoline-6-yl, 2-isopropyl-methylamino-quinoline-6-yl, 2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl, quinoxaline-6-yl, 1-oxo-isoindoline-5-yl, 2-isopropyl-1-oxo-isoindoline-5-yl, 2-(2,2-difluoroethyl)-1-oxo-isoindoline-5-yl, 2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoindoline-5-yl, 2-methyl-1-oxo-isoindoline-5-yl, 2-cyclopropyl-1-oxo-isoindoline-5-yl, 2-ethyl-1-oxo-isoindoline-5-yl, and 2-(2-hydroxy-1-methylethyl)-1-oxo-isoindoline-5-yl.

38. (New) The compound of Claim 36 wherein R<sup>1</sup> is 2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl.

39. (New) The compound of Claim 36 wherein R<sup>1</sup> is 2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl.

40. (New) The compound of Claim 36 wherein R<sup>2</sup> represents a group selected from the group consisting of: lower alkyl group, and cyano group.

41. (New) A compound which is selected from the group consisting of:  
5-methyl-1-phenyl-4-(quinoline-6-yl)-1H-[1,2,3]triazole,  
4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole, and  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole,  
or a pharmaceutically acceptable salt thereof.

42. (New) The compound of Claim 41 which is selected from the group consisting of:  
4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole;  
or a pharmaceutically acceptable salt thereof.

43. (New) A compound which is selected from the group consisting of:  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole,  
or a pharmaceutically acceptable salt thereof.

44. (New) The compound of Claim 46 which is:  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole.

45. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 36, or a pharmaceutically acceptable salt thereof.

46. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 41, or a pharmaceutically acceptable salt thereof.

47. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 42, or a pharmaceutically acceptable salt thereof.

48. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 43, or a pharmaceutically acceptable salt thereof.

49. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 44, or a pharmaceutically acceptable salt thereof.